



Anand Nagar, Krishnankoil - 626126, Srivilliputtur (via), Virudhunagar District, Tamilnadu.

APPLICATION FOR ADMISSION TO Ph.D. PROGRAMMES

Date of Application:24-12-2020

Department	BIOTECHNOLOGY	Application No.	202020187
Area of Research	BIOCHEMISTRY	Research Mode	PART TIME

Name :KRISHNAKUMAR
Date of Birth / Age :03-02-1971 / 49 Years
Gender :MALE
Category :BC
e-Mail ID :krishnak@thyrocare.com
Mobile :8451939706



Father's/Husband's Name	SIVAPANDI	Father's/Husband's Occupation	FARMER
Family Income	20 LAKH	Residential Type	RURAL
Birth Place	AVUDAIALPURAM, IDINDAKARI(PO), NELLAI(DT), TAMIL NADU	Mother Tongue	TAMIL
Religion	HINDU	Martial Status	MARRIED
Aadhaar No.	537368785407	PAN No.	BCYPK4769F
Physically Challenged	NO	Type of Disability	-
Address for Communication: E-201, SECOND FLOOR, PANCHAVATI PLAZA PLOT NO 92 - 96, SECTOR-5, GHANSOLI NAVIMUMBAI THANE DISTRICT MAHARASHTRA INDIA Pin-400701		Permenant Address: S/O.SIVAPANDI, NORTH STREET AVUDAIALPURAM, IDINDAKARAI (PO) RADHAPURAM(TK) TIRUNELVELI DISTRICT TAMILNADU INDIA Pin-627104	

Qualification						
Degree	Discipline	College/university	Year Passed	AVG/CGPA	Class	Mode
B.SC	ZOOLOGY	MANONMANIAM SUNDARANAR UNIVERSITY	1993	76.6	FIRST	REGULAR
M.SC	ZOOLOGY	MANONMANIAM SUNDARANAR UNIVERSITY	1995	62.9	FIRST	REGULAR

Experience					
Organization	Designation	Experience From	Experience TO	Work Nature	
THYROCARE TECH PVT LTD	DY.GENERAL MANAGER	2001-03-01	1970-01-01	CLINICAL LABORATORY	

Payment Details				
Transaction ID	Reference	Date of transaction	Amount	Status
202020187_201224142734	VHMP9590479460	24-12-2020	600	SUCCESS

Research Proposal

Running Title: Prevalence and clinical patterns of hemoglobinopathies diagnosis in Indian population by using CE-HPLC method : A pilot study

Background of research area :

The hemoglobinopathies comprise inherited disorders of the structure or synthesis of hemoglobin. They are the commonest single gene disorders in the world. It is estimated that about 450,000 infants with hemoglobinopathies are born in the world. Almost 85.9% of these hemoglobinopathies are sickle cell disease (SCD). Births of children with β -thalassemia alone or combined with hemoglobin (Hb) E are about 44, 000 (9.7%) per year, whereas infants affected with Hb Barts and HbH disease are about 20,000 (4.4%). Approximately 80% of the annual births of babies with these disorders occur in low- or middle-income countries. These disorders originated in populations in tropical Africa, Asia, and the Mediterranean region and have spread via migration throughout the world. They are, therefore, of concern in all countries

Literature of review

The prevention of inherited haemoglobinopathies has been internationally recognized as a health priority for several decades (Cousens et al. 2010). Both voluntary programmes to identify carriers in high school students (Mitchell et al. 1996; Amato et al. 2014) and mandatory premarital testing (Bozkurt 2007; Loukopoulos 2011; Alswaidi et al. 2012) have been successfully employed, with the reduction in affected births achieved via an informed decision made by carriers either regarding their choice of partner or early prenatal testing and selective termination of pregnancy (Giordano 2009; Miri et al. 2013).

The current population of India is estimated to be 1.37 billion (PRB 2018), equivalent to 18% of the global total and despite rapid urbanisation some 67% of people in India continue to live in rural areas. In terms of health indicators, the rural population significantly lags their urban counterparts, as reflected by the rural infant mortality rate of 38/1000 live births compared with 23/1000 in towns and cities (RGI 2017). Further, differences within the country, both in terms of the prevalence and causes of diseases across the 29 states, are highlighted in the recent comprehensive report on the burden of disease at the individual state level. The report also confirms a significant overall shift from communicable to non-communicable diseases, with congenital defects listed among the 20 commonest causes of disease listed (India State-Level Disease Burden Initiative Collaborators 2017). The genetic diversity of the Indian population, with large numbers of endogamous ethnic, geographical, religious and social groupings each with extended, unbroken genealogical histories, adds to the complexity of the prevalence and burden of genetic disorders (Basu et al. 2016; Nakatsuka et al. 2017), as observed in regional and caste-specific analyses of mutation data on haemoglobinopathies (Sinha et al. 2009; Black et al. 2010; Trehan et al. 2015).

My Aim and Objectives: (Hemoglobinopathies in India—Clinical and Laboratory Aspects)

1. To study the different clinical patterns of hemoglobinopathies diagnosed by high-performance liquid chromatography (HPLC) in India population.
2. This pilot study is aimed to find the prevalence of hemoglobinopathies in India and identify the change in the demographic profile.

Data collection and laboratory Analytical Methods:

1. Sysmex XN9000 Hematology 6 part analyzer 2. Biorad variant II (CE HPLC) 3. Sebia CE

Study design & Statistical resource :**Expected outcome and research recommendation:**

The Government of India is presently engaged in the implementation of a prevention and control programme for two major forms of haemoglobinopathies, thalassaemia major and sickle cell disease, with guidelines for their prevention and management formulated under the National Health Mission. Based on projections for the population up to the year 2026, the annual blood requirement for treatment will increase to 9.24 million units, together with an 86% increase in budgetary requirements which then would account for over 19% of the current National Health Budget. To avert a public health crisis there is an urgent need to fully implement the prevention programme for haemoglobinopathies.

From the above projections and the assessment of available resources, it is evident that effective implementation of well-designed and efficiently implemented prevention strategies is urgently required. In India, screening for the detection of carriers in an annual cohort of adolescents in schools and/or of all pregnant women is the most feasible prevention strategy available for reducing the birth of children affected with thalassaemia. Besides improving genetic literacy in the population, an important side benefit of such screening programmes would be the capacity to derive accurate, representative data on the incidence of the major haemoglobinopathies at state and community levels which, in turn, would facilitate the compilation of comprehensive disease registries.


Reference:

Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB (2010) Carrier screening for Beta-thalassaemia: a review of international practice. *Eur J Hum Genet* 18:1077–1083

Mitchell JJ, Capua A, Clow C, Scriver CR (1996) Twenty-year outcome analysis of genetic screening programs for Tay-Sachs and β -thalassemia disease carriers in high schools. *Am J Hum Genet* 59:793–798

Giordano PC (2009) Prospective and retrospective primary prevention of hemoglobinopathies in multiethnic societies. *Clin Biochem* 42:

Sujata Sinha et al (2020). Haemoglobinopathies in India: estimates of blood requirement and treatment costs for the decade 2017–2026, *J Community Genet*, 11:39–45



MANONMANIAM SUNDARANAR UNIVERSITY

B.Sc. Degree Examination (Semester System)

STATEMENT OF MARKS SL. NO. **H13831**

NAME OF THE CANDIDATE				REG. NO.	BR.	DATE OF PUBLICATION											
K R I S H N A K U M A R S				90614080	Z	02/7/93											
COLLEGE OF STUDY				COLL. NO.	CEN. NO.	EXAM M & YR.											
ADITANAR COLLEGE - TIRUCHENDUR				416	436	2FR/93											
SUB.	MARKS	R	M./YR.	SUB.	MARKS	R	M./YR.	SUB.	MARKS	R	M./YR.						
I E T			I E T			I E T											
PART I - LANGUAGE			PART II - ENGLISH			PART III - MAJOR											
1A1	18	30	48	P	N90	3A1	16	32	48	P	N90	Z6F	21	54	75	F	A93
1A2	20	36	56	P	A91	3A2	15	23	38	P	A91	ZA1	17	53	70	F	N90
1A3	18	37	55	P	N91	3A3	16	31	47	P	N91	ZB2	27	52	74	F	A91
1A4	18	45	63	F	A92	3A4	16	35	51	P	A92	ZC3	19	61	80	F	N91
PART III - ANCILLARY - I			PART III - ANCILLARY - II			ZD4			23	51	74	F	A92				
SE1	11	24	35	F	N90	SS1	10	30	40	P	N91	ZE5	24	35	59	F	N92
SE2	11	29	40	F	A91	SS2	11	27	38	P	A92	ZF5	21	42	63	F	N92
SE3	10	25	35	F	N91	SS3	10	23	43	P	N92	ZG5	21	64	85	F	N92
SE4	12	34	46	F	A92	SS4	11	31	42	P	A93	ZH0	17	35	52	F	A93
SE5	17	34	51	P	A91	SS5	24	24	48	P	A92	ZJ6	23	37	60	F	A93
SE6	26	30	56	F	A92	SS6	24	24	48	P	A93	ZR1	36	40	82	F	A91
												ZR2	50	38	88	F	A92
												ZR3	45	40	85	F	A93
PART I - LANGUAGE			PART II - ENGLISH			PART III											
TOTAL MARKS	CLASS		TOTAL MARKS	CLASS		TOTAL MARKS	CLASS										
222	/400		184	/400		1456	/2900										
	SECCND			THIRD			FIRST										

Signature of the Candidate: *S. Krishnakumar*

Any alteration or overwriting makes this Statement of Marks invalid.

Signature of the Examiner: *R. S. A. Sunderlingh*
 Prof. R. S. A. SUNDERLINGH
 Controller of Examinations

Thyrocare®
Think Thyroid. Think Thyrocare.

21/08/2020

To whom so ever it may concern


Mr. Krishnakumar Sivapandi, General Manager at Thyrocare Technologies Limited is with us from the year 2001. "Inquisitive" and "Seeker" are the two adjectives that best describe his personality and has helped him grow to the position he handles today in the organization. A motivation force for the laboratory processing staff he ensures the 24*7 operations are well supported.

His knowledge on tests and technologies has grown manifold and today executes biochemical test validation and monitors performance with ease. Having supervised millions of biochemical and pathological tests for over 19 years now, his knowledge on science grows each day.

He has expertise in;


1. Chemiluminescence Immunoassay
2. Analytical Chemistry
3. Flow cytometry
4. Polymerase Chain Reaction

His experience as a researcher and administrator makes it worth working for a doctorate degree.


Dr. A. Velumani

Thyrocare Technologies Limited
D-37/1, TTC MIDC, Turbhe, Navi Mumbai - 400 703, India ☎ 022- 3090 0000 / 4125 2525
✉ enquiry@thyrocare.com 🌐 www.thyrocare.com
(CIN : L85110MH2000PLC123882)





*CERTIFICATE No.

2187435



DISTRICT CODE 18

TALUK CODE 09

VILLAGE CODE 029

COMMUNITY CERTIFICATE

This is to certify that..... **S. KRISHNA KUMAR**.....
 son/daughter of Thiru... **P. Sivapandi Nadar**.....
 of **Dundayalpuram** to **Vijayapally** village/town... **Radhapuram**..... taluk
Kovvur taluk... **Kattalambur**..... district of the State of Tamil Nadu
 belongs to..... **Hindu Nadar**..... community, which
 is recognised as a ~~Most Backward Class/Denotified Community/~~
~~Backward Class/Scheduled Caste/Scheduled Tribe~~ as per
 G.O. Ms. No..... **123**..... Dated... **25.7.89**...../The
S.C. and S.T. Orders (Amendment) Act, 1976, vide Sl. No... 118....

2. It is certified that.....; and
 his/her family ordinarily reside(s) at.....
 village/town..... taluk.....
 district of the State of Tamil Nadu.



Signature :

Date :

Seal:

Name in capital letters :

Designation :

**Head Quarters Deputy Tahsildar
RADHAPURAM.**

* This Certificate must be filled in the Application Forms.
 NOTE.—Competent Authorities for issue of Certificate for SC/STs, except Konda Reddis,
 Taluk Tahsildars; for Konda Reddis, R.D.O.'s; for B.Cs. and O.Cs., Head Quarter's
 Deputy Tahsildars/Special Deputy Tahsildars.

ANNEXURE-I

CERTIFICATE FROM THE ORGANISATION WHERE THE CANDIDATE IS EMPLOYED

Certified that Mr./~~Ms.~~/Mrs. KRISHNAKUMAR is employed as GENERAL MANAGER (Designation) in the LABORATORY (Department/Division Name) of THYROCARE TECHNOLOGIES LTD (Institution/Industry Name).


We have no objection in forwarding his/her application for the Ph.D. Research Programme.

FOR FULL TIME:

The candidate will be sanctioned leave for the duration of the research programme and will be relieved from duty from _____ to _____ to undertake the full time research work in the University.

FOR PART TIME:

The candidate will be permitted to undertake part time study in the University/College and will be allowed to be present for discussions with the supervisor, attending course works, conduct of experiments and participations in seminars and related presentations. Further the required facilities at our organization will also be provided to the candidate for doing research.





Date: 23.12.2020

Signature of the Head of Organization with office seal